New Findings Reported from Villejuif Describe Advances in Medullary Thyroid Cancer [Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A...].

MLA

“New Findings Reported from Villejuif Describe Advances in Medullary Thyroid Cancer [Safety and Efficacy of Nintedanib as Second-Line Therapy for Patients with Differentiated or Medullary Thyroid Cancer Progressing after First-Line Therapy. A...].” Clinical Trials Week, July 2024, p. 610. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=178392509&authtype=sso&custid=ns315887.

APA

New Findings Reported from Villejuif Describe Advances in Medullary Thyroid Cancer [Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A...]. (2024). Clinical Trials Week, 610.

Chicago

“New Findings Reported from Villejuif Describe Advances in Medullary Thyroid Cancer [Safety and Efficacy of Nintedanib as Second-Line Therapy for Patients with Differentiated or Medullary Thyroid Cancer Progressing after First-Line Therapy. A...].” 2024. Clinical Trials Week, July, 610. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=178392509&authtype=sso&custid=ns315887.